<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03324139</url>
  </required_header>
  <id_info>
    <org_study_id>FSJD-TRACIP-2017</org_study_id>
    <secondary_id>2017-001905-33</secondary_id>
    <nct_id>NCT03324139</nct_id>
  </id_info>
  <brief_title>Treatment of Intrauterine Growth Restriction With Low Molecular Heparin.</brief_title>
  <acronym>TRACIP</acronym>
  <official_title>Treatment of Intrauterine Growth Restriction With Low Molecular Heparin: Randomized Clinical Trial. Tratamiento Del Crecimiento Intrauterino Restringido Precoz Con Heparina de Bajo Peso Molecular: Ensayo clínico Aleatorizado.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Sant Joan de Déu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Servicio de Asesoría a la Investigación y Logística SL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Sant Joan de Déu</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TREATMENT OF INTRAUTERINE GROWTH RESTRICTION WITH LOW MOLECULAR WEIGHT HEPARIN.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TREATMENT OF INTRAUTERINE GROWTH RESTRICTION WITH LOW MOLECULAR WEIGHT HEPARIN: RANDOMIZED
      CLINICAL TRIAL (TRACIP STUDY).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized, double-blind, two-parallel, placebo-controlled, phase III multicenter clinical trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of low molecular weight heparin in the prolongation of gestation.</measure>
    <time_frame>13 weeks maximum</time_frame>
    <description>Measured as gestational age (weeks) at birth (dated by ultrasonography &lt;14 weeks by measurement of caudal skull length).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of low molecular weight heparin in reducing neonatal morbidity</measure>
    <time_frame>13 weeks maximum</time_frame>
    <description>Measured as the presence of one or more of the following: Perinatal mortality (&gt; 22 weeks of gestation - &lt;28 days postpartum), Significant neonatal morbidity (convulsions, intraventricular haemorrhage&gt; grade III, periventricular leukomalacia, hypoxic-ischemic encephalopathy, abnormal electroencephalogram, necrotizing enterocolitis, acute renal failure (serum creatinine&gt; 1.5 mg / dL) or cardiac failure (requiring inotropic agents), Perinatal mortality (22 weeks to 28 postnatal days), Biomarkers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Demonstrate that low molecular weight heparin improves the pro-angiogenic and anti-inflammatory profile.</measure>
    <time_frame>13 weeks maximum</time_frame>
    <description>Measured as the presence of one or more of the following: mother blood biomarkers (sFlt and PlGF), biomerkers, umbilical cord blood biomarkers (TNF alfa, IL6, IFN gamma, FGF basic, VEGF and PlGF), mRNA in trophoblast.( IL6, INFg, TNF alfa, VEGFA, VEGFB, FGF2 y RQVEGF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of low molecular weight heparin in reducing thrombotic and ischemic placental lesions</measure>
    <time_frame>13 weeks maximum</time_frame>
    <description>Measured as the presence of one or more of the following: Intrauterine growth retardation (Neonatal weight below the 10th percentile of our population + umbilical artery pulsatility index during the third trimester (on two separate occasions&gt; 48h) above the 95th percentile), Preeclampsia, Gestational age (weeks) at birth, Premature delivery before 34 weeks of gestation, Urgent cesarean section due to loss of fetal well-being, Neonatal weight, Neonatal acidosis (arterial pH &lt;7.10 + EB&gt; 12mEq / L), Days stay in the Neonatal Intensive Care Unit, mRNA in trophoblast.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Intrauterine Growth Restriction</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with low molecular weight Heparin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment with Placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low molecular weight heparin</intervention_name>
    <description>Patients included in this study group will receive 3,500 IU / 0.2 ml / day of Bemiparina sc, from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).</description>
    <arm_group_label>Study Group</arm_group_label>
    <other_name>heparin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Patients included in this study group will placebo (same presentation as the active drug), from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>sodium chloride (0.9%)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women older than 18 years.

          -  Unique gestations

          -  Diagnosis of early placental intrauterine growth (according to Delphi classification):
             &lt;32 weeks at diagnosis + Doppler AU with absent / reverse flow or (estimated fetal
             weight &lt;10 percentile + pulsed Doppler ultrasonography) or (estimated fetal weight
             &lt;percentile 10 + pulsed uterine artery Doppler).

          -  Patient giving written informed consent to participate in the study.

        Exclusion Criteria:

          -  Chromosopathies, genetic alterations or fetal malformations.

          -  Diagnostic treatment with low molecular weight heparins, oral anticoagulants or
             acetylsalicylic acid prior to inclusion.

          -  History of heparin-induced thrombocytopenia.

          -  Active hemorrhage or increased risk of bleeding due to changes in hemostasis.

          -  Severe hepatic or pancreatic function disorder.

          -  Organic lesions that may bleed (eg, active peptic ulcer, hemorrhagic stroke,
             aneurysms, or brain tumors).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edurne Mazarico</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Sant Joan de Deu</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ainhoa Andueza</last_name>
    <phone>+34 93 600 97 33</phone>
    <phone_ext>70043</phone_ext>
    <email>aandueza@fsjd.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Sant Joan de Déu</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edurne Mazarico Gallego, MD Ph</last_name>
      <email>emazarico@sjdhospitalbarcelona.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2017</study_first_submitted>
  <study_first_submitted_qc>October 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2017</study_first_posted>
  <last_update_submitted>October 23, 2017</last_update_submitted>
  <last_update_submitted_qc>October 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Growth Retardation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

